This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday, April 4, 2024 it will pull the medicine from the U.S. market, acknowledging it didn't help patients with the deadly neurological condition. (Amylyx Pharmaceuticals via AP)
April 4, 2024
Stories this photo appears in:
April 4, 2024 11:45 a.m.
ALS drug will be pulled from US market after study showed patients didn't benefit
The drug's failure is a bitter disappointment for patients and advocates, who have pressed the FDA and other federal agencies to fund and approve more experimental therapies for the fatal muscle-wasting disease.